Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody

[1]  R. Tsang,et al.  Hodgkin’s lymphoma , 2018, Concise Notes in Oncology for MRCP and MRCS.

[2]  W. Mcbride,et al.  Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods , 2005, Clinical Cancer Research.

[3]  J. Vose,et al.  Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. , 2004, Blood.

[4]  L. Gordon,et al.  Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. , 2004, Blood.

[5]  D. Goldenberg,et al.  Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin’s Lymphoma , 2004, Clinical Cancer Research.

[6]  J. Vose.  Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. , 2004, The oncologist.

[7]  W. Mcbride,et al.  Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  W. McBride,et al.  Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  W. Oyen,et al.  Pretargeted radioimmunotherapy of cancer: progress step by step. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  W. McBride,et al.  Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods? , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Gary L Griffiths,et al.  A universal pretargeting system for cancer detection and therapy using bispecific antibody. , 2003, Cancer research.

[12]  L. Gordon,et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Damon L. Meyer,et al.  A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. , 2001, Blood.

[14]  P. Weiden,et al.  Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL). , 2001, Critical reviews in oncology/hematology.

[15]  J. Vose,et al.  Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E. Gautherot,et al.  In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  J. Vose,et al.  Phase 1 trial of a novel anti-CD 20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma , 2004 .

[18]  G. Griffiths,et al.  90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.